Oncolytics Biotech (TSE:ONC) Sets New 1-Year Low at $1.20

Shares of Oncolytics Biotech Inc. (TSE:ONC) reached a new 52-week low on Wednesday . The company traded as low as C$1.20 and last traded at C$1.22, with a volume of 16001 shares. The stock had previously closed at C$1.22.

Analysts Set New Price Targets

Separately, Raymond James increased their price objective on shares of Oncolytics Biotech from C$3.00 to C$3.50 in a report on Friday, September 20th.

Oncolytics Biotech Stock Performance

The company has a debt-to-equity ratio of 6.09, a quick ratio of 8.86 and a current ratio of 4.99. The stock’s fifty day moving average is C$1.33 and its two-hundred day moving average is C$1.42. The firm has a market cap of C$92.23 million, a price-to-earnings ratio of -3.18 and a beta of 1.38.

Oncolytics Biotech (TSE:ONC) last released its quarterly earnings data on Thursday, August 1st. The company reported C($0.10) earnings per share for the quarter, hitting analysts’ consensus estimates of C($0.10). On average, analysts expect that Oncolytics Biotech Inc. will post -0.41 earnings per share for the current fiscal year.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.